Who are we?
Contributing to ground-breaking, world-first medical research.
{About
Since 1985, AusHealth has returned more than $45 million to medical research, contributing to ground-breaking, world-first discoveries and the development of leading-edge medical technologies.
We have been successful in licensing these technologies to companies today worth $1.7 billion and we have assisted in bringing tens of millions of dollars to support research.
We are the exclusive commercialisation agent for the Central Adelaide Local Health Network, which includes the Royal Adelaide Hospital (RAH), the Queen Elizabeth Hospital (TQEH) and SA Pathology, although we also routinely partner with universities and medical research institutes in Australia and internationally to assist with developing their medical research.
AusHealth Research continues to invest all profits into developing new ideas and commercializing intellectual property, including technology from the RAH, TQEH and SA Pathology.
Constantly looking for new technologies and research.
{How we work
We partner hand-in-hand with Central Adelaide Local Health Network (CALHN), including The Royal Adelaide Hospital (RAH), The Queen Elizabeth Hospital (TQEH) and SA Pathology, as well as other Australian hospitals in providing funding to develop and commercialize new technologies and research.
We’re also passionate about showcasing the high-quality research currently being undertaken in our South Australian backyard.
All revenues received are then reinvested back into our other ongoing projects, ensuring that we’re always pushing towards new developments.
We partner with researchers from the very beginning.
{Partner with us
We partner with you from the very beginning — we assess the best pathway for your project to the healthcare market, create and monitor a corporate business plan favoured by the industry, all the way to commercialisation – including licensing, trade sale, company creation or joint venture collaboration.
Partnering with us means we take care of the due diligence, intellectual property, while you can focus on what’s really important – your research.
We have a number of ventures already in partnership and under funding.